In CRC, the switch of immune-stimulating M1 cells in favor of the immune-suppressive M2-like cells not only foster tumor growth and progression [80] but also promotes resistance to therapy [57, 81–84]; this possibility suggests that the expression levels of EMILIN-2 may also affect the efficacy of CRC treatment. This evidence concerns the gene EMILIN2 and colorectal carcinoma.